RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsONCY's pelareorep is a "Phase 3 ready" drug in preparation for the FDA's recently sought reforms in the accelerated approval process that will be be codified in the new Congress Spending Bill, thus placing ONCY in a position to ask the FDA for an accelerated approval at the time the Bracelet-1 ORR and PFS results are announced.
Furthermore ONCY's Phase 2 results in pancreatic cancer offer another opportunity to follow the newly reformed accelerated approval process.